scispace - formally typeset
S

Scott L. Friedman

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  517
Citations -  74268

Scott L. Friedman is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Hepatic stellate cell & Fibrosis. The author has an hindex of 126, co-authored 488 publications receiving 62931 citations. Previous affiliations of Scott L. Friedman include Washington University in St. Louis & Instituto de Medicina Molecular.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Mechanisms of Hepatic Fibrogenesis

Scott L. Friedman
- 01 May 2008 - 
TL;DR: Clinical and translational implications of these advances have become clear, and have begun to impact significantly on the management and outlook of patients with chronic liver disease.
Journal ArticleDOI

Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver

Scott L. Friedman
- 01 Jan 2008 - 
TL;DR: The hepatic stellate cell has surprised and engaged physiologists, pathologists, and hepatologists for over 130 years, yet clear evidence of its role in hepatic injury and fibrosis only emerged following the refinement of methods for its isolation and characterization.
Journal ArticleDOI

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.

Scott L. Friedman
- 28 Jan 2000 - 
TL;DR: Establishing the importance of the normal ECM in liver has illuminated recent attempts to develop artificial liver support by recognizing that all cellular elements and supporting structures must be reconstituted to preserve differentiated function of liver ex vivo.
Journal ArticleDOI

Mechanisms of NAFLD development and therapeutic strategies

Scott L. Friedman, +3 more
- 02 Jul 2018 - 
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.